KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Other financing activities (2019 - 2025)

Vir Biotechnology (VIR) has disclosed Other financing activities for 5 consecutive years, with -$2000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities fell 115.38% to -$2000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$28000.0 through Dec 2025, up 83.03% year-over-year, with the annual reading at -$361000.0 for FY2025, 118.79% down from the prior year.
  • Other financing activities hit -$2000.0 in Q4 2025 for Vir Biotechnology, down from $1000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $100000.0 in Q1 2023 to a low of -$387000.0 in Q4 2023.
  • Historically, Other financing activities has averaged -$89125.0 across 4 years, with a median of -$21000.0 in 2024.
  • Biggest five-year swings in Other financing activities: skyrocketed 103.36% in 2024 and later plummeted 115.38% in 2025.
  • Year by year, Other financing activities stood at -$260000.0 in 2022, then crashed by 48.85% to -$387000.0 in 2023, then surged by 103.36% to $13000.0 in 2024, then tumbled by 115.38% to -$2000.0 in 2025.
  • Business Quant data shows Other financing activities for VIR at -$2000.0 in Q4 2025, $1000.0 in Q3 2025, and $13000.0 in Q4 2024.